Trial Profile
Phase I/II study of Taxotere (docetaxel), Eloxatin (oxaliplatin) and Xeloda (capecitabine) as first line treatment to patients with non-resectable ventricular cancer and/or distal esophageal cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2012
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Jun 2011 New trial record